As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...